Theranostic magnetic nanostructures (MNS) for Cancer

Cancer Treatment and Research

Volumn 166, Issue , 2015, Pages 51-83

  Nandwana, Vikas ^a   De, Mrinmoy ^b   Chu, Shihyao ^c   Jaiswal, Manish ^d   Rotz, Matt ^e   Meade, Thomas J ^e   Dravid, Vinayak P ^a  

^a Northwestern University   (United States)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c SANDIA NATIONAL LABORATORIES   (United States)

^d Texas A M University   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Magnetic nanostructures; MR imaging; T2 contrast agents; Theranostics; Thermal activation

Indexed keywords

COPPER; DEXTRAN; DRUG CARRIER; FERRITE; FERUCARBOTRAN; FERUMOXSIL; IRON; MACROGOL; MAGNETIC NANOPARTICLE; METAL ION; NICKEL; SILICON DIOXIDE; SUPERPARAMAGNETIC IRON OXIDE; METAL NANOPARTICLE;

ABSORPTION; ACTIVE TARGETING; ARTICLE; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER THERAPY; CHEMICAL COMPOSITION; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DIFFUSION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; HYPERTHERMIA; LIVER FUNCTION; MAGNETIC FIELD; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PASSIVE TARGETING; PHARMACOKINETICS; PRIORITY JOURNAL; RADIOFREQUENCY; RETICULOENDOTHELIAL SYSTEM; TUMOR LOCALIZATION; ANIMAL; HEAT; HYPERTHERMIC THERAPY; MAGNETISM; NEOPLASMS; PROCEDURES;

ANIMALS; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC RESONANCE IMAGING; MAGNETICS; METAL NANOPARTICLES; NANOMEDICINE; NEOPLASMS;

EID: 84928578518     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-16555-4_3     Document Type: Article

References (170)

1. Kim J, Piao Y, Hyeon T (2009) Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem Soc Rev 38(2):372-390
2. Sun C, Lee JSH, Zhang MQ (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60(11):1252-1265
3. Ho D, Sun XL, Sun SH (2011) Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res 44(10):875-882
4. Yoo D et al (2011) Theranostic magnetic nanoparticles. Acc Chem Res 44(10):863-874
5. Veiseh O, Gunn JW, Zhang MQ (2010) Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 62(3):284-304
6. Xu CJ, Sun SH (2013) New forms of superparamagnetic nanoparticles for biomedical applications. Adv Drug Deliv Rev 65(5):732-743
7. Cole AJ, Yang VC, David AE (2011) Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol 29(7):323-332
8. Livingston JD (1981) A review of coercivity mechanisms. J Appl Phys 52(3):2544-2548
9. Reddy LH et al (2012) Magnetic nanoparticles: design and characterization, toxicity and biocompatibility. Pharmaceutical and biomedical applications. Chem Rev 112 (11):5818-5878
10. McCarthy JR, Weissleder R (2008) Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60(11):1241-1251
11. Misra RDK (2008) Magnetic nanoparticle carrier for targeted drug delivery: perspective, outlook and design. Mater Sci Technol 24(9):1011-1019
12. Kievit FM, Zhang MQ (2011) Surface engineering of iron oxide nanoparticies for targeted cancer therapy. Acc Chem Res 44(10):853-862
13. Jun YW, Lee JH, Cheon J (2008) Chemical design of nanoparticle probes for highperformance magnetic resonance imaging. Angew Chem Int Ed 47(28):5122-5135
14. Lee N, Hyeon T (2012) Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem Soc Rev 41(7):2575-2589
15. De M et al (2011) Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev 63(14-15):1282-1299
16. Caravan P et al (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99(9):2293-2352
17. Caravan P (2006) Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35(6):512-523
18. Frullano L, Meade TJ (2007) Multimodal MRI contrast agents. J Biol Inorg Chem 12 (7):939-949
19. Na HB, Hyeon T (2009) Nanostructured T1 MRI contrast agents. J Mater Chem 19 (35):6267-6273
20. Na HB, Song IC, Hyeon T (2009) Inorganic nanoparticles for MRI contrast agents. Adv Mater 21(21):2133-2148
21. Hahn PF et al (1990) 1st clinical-trial of a new superparamagnetic iron-oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 175(3):695-700
22. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13(6):1266-1276
23. Koenig SH, Kellar KE (1995) Theory of 1/T1 and 1/T2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med 34(2):227-233
24. Jordan A et al (1999) Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater 201:413-419
25. Fortin JP et al (2007) Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. J Am Chem Soc 129(9):2628-2635
26. Hergt R, Dutz S (2007) Magnetic particle hyperthermia-biophysical limitations of a visionary tumour therapy. J Magn Magn Mater 311(1):187-192
27. Jun YW et al (2005) Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 127(16):5732-5733
28. Laurent S et al (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108(6):2064-2110
29. Roca AG et al (2009) Progress in the preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 42(22):224002
30. Massart R (1981) Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn 17(2):1247-1248
31. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18):3995-4021
32. Loo AL et al (2008) Synthesis of magnetic nanoparticles in bicontinuous microemulsions. Effect of surfactant concentration. J Mater Sci 43(10):3649-3654
33. Murray CB, Kagan CR, Bawendi MG (2000) Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies. Annu Rev Mater Sci 30:545-610
34. Park J et al (2004) Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater 3 (12):891-895
35. Wang YXJ, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11 (11):2319-2331
36. Jung CW, Jacobs P (1995) Physical and chemical-properties of superparamagnetic iron-oxide MR contrast agents-ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 13 (5):661-674
37. Lee JH et al (2006) Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. Angew Chem Int Ed 45 (48):8160-8162
38. Lee JH et al (2007) Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 13(1):95-99
39. Tong S et al (2010) Coating optimization of superparamagnetic iron oxide nanoparticles for high T-2 relaxivity. Nano Lett 10(11):4607-4613
40. Lee N et al (2011) Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci USA 108 (7):2662-2667
41. Barcena C et al (2008) Zinc ferrite nanoparticles as MRI contrast agents. Chem Commun 19:2224-2226
42. Jang JT et al (2009) Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew Chem Int Ed 48(7):1234-1238
43. Seo WS et al (2006) FeCo/graphitic-shell nanocrystals as advanced magnetic-resonanceimaging and near-infrared agents. Nat Mater 5(12):971-976
44. Lacroix LM et al (2011) Stable single-crystalline body centered cubic Fe nanoparticles. Nano Lett 11(4):1641-1645
45. Lee H, Yoon TJ, Weissleder R (2009) Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system. Angew Chem Int Ed 48(31):5657-5660
46. Yoon TJ et al (2011) Highly magnetic core-shell nanoparticles with a unique magnetization mechanism. Angew Chem Int Ed 50(20):4663-4666
47. Hu FQ et al (2010) High-performance nanostructured MR contrast probes. Nanoscale 2 (10):1884-1891
48. Hu FQ et al (2010) Highly dispersible, superparamagnetic magnetite nanoflowers for magnetic resonance imaging. Chem Commun 46(1):73-75
49. Morales MP et al (1999) Surface and internal spin canting in gamma-Fe2O3 nanoparticles. Chem Mater 11(11):3058-3064
50. Puntes VF, Krishnan KM, Alivisatos AP (2001) Colloidal nanocrystal shape and size control: the case of cobalt. Science 291(5511):2115-2117
51. Cordente N et al (2001) Synthesis and magnetic properties of nickel nanorods. Nano Lett 1 (10):565-568
52. Desvaux C et al (2005) Multimillimetre-large superlattices of air-stable iron-cobalt nanoparticles. Nat Mater 4(10):750-753
53. Schutz-Sikma EA et al (2011) Probing the chemical stability of mixed ferrites: implications for magnetic resonance contrast agent design. Chem Mater 23(10):2657-2664
54. Colombo M et al (2012) Biological applications of magnetic nanoparticles. Chem Soc Rev 41(11):4306-4334
55. Bao YP, Krishnan KM (2005) Preparation of functionalized and gold-coated cobalt nanocrystals for biomedical applications. J Magn Magn Mater 293(1):15-19
56. Peng S et al (2006) Synthesis and stabilization of monodisperse Fe nanoparticles. J Am Chem Soc 128(33):10676-10677
57. Ni XM et al (2010) Silica-coated iron nanoparticles: shape-controlled synthesis, magnetism and microwave absorption properties. Mater Chem Phys 120(1):206-212
58. Cozzoli PD, Pellegrino T, Manna L (2006) Synthesis, properties and perspectives of hybrid nanocrystal structures. Chem Soc Rev 35(11):1195-1208
59. Donega CD (2011) Synthesis and properties of colloidal heteronanocrystals. Chem Soc Rev 40(3):1512-1546
60. Gao JH, Gu HW, Xu B (2009) Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res 42(8):1097-1107
61. Xu CJ, Wang BD, Sun SH (2009) Dumbbell-like Au-Fe3O4 nanoparticles for target-specific platin delivery. J Am Chem Soc 131(12):4216-4217
62. Gu HW et al (2004) Facile one-pot synthesis of bifunctional heterodimers of nanoparticles: a conjugate of quantum dot and magnetic nanoparticles. J Am Chem Soc 126(18):5664-5665
63. Kwon KW, Shim M (2005) gamma-Fe2O3/II-VI sulfide nanocrystal heterojunctions. J Am Chem Soc 127(29):10269-10275
64. Choi JH et al (2007) Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes. Nano Lett 7(4):861-867
65. Gao JH et al (2007) Fluorescent magnetic nanocrystals by sequential addition of reagents in a one-pot reaction: a simple preparation for multifunctional nanostructures. J Am Chem Soc 129(39):11928-11935
66. Pittet MJ et al (2006) Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat Protoc 1(1):73-79
67. Wang DS et al (2004) Superparamagnetic Fe2O3 Beads-CdSe/ZnS quantum dots core-shell nanocomposite particles for cell separation. Nano Lett 4(3):409-413
68. Choi JS et al (2010) Self-confirming "AND" logic nanoparticles for fault-free MRI. J Am Chem Soc 132(32):11015-11017
69. Gupta AK et al (2007) Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2(1):23-39
70. Kohler N, Fryxell GE, Zhang MQ (2004) A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 126(23):7206-7211
71. Xie J et al (2007) Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater 19(20):3163-3166
72. Mornet S, Portier J, Duguet E (2005) A method for synthesis and functionalization of ultrasmall superparamagnetic covalent carriers based on maghemite and dextran. J Magn Magn Mater 293(1):127-134
73. Kim DH et al (2009) Targeting to carcinoma cells with chitosan- and starch-coated magnetic nanoparticles for magnetic hyperthermia. J Biomed Mater Res Part A 88A(1):1-11
74. Pradhan P et al (2010) Targeted temperature sensitive magnetic liposomes for thermochemotherapy. J Controlled Release 142(1):108-121
75. Wang LY et al (2008) Core@shell nanomaterials: gold-coated magnetic oxide nanoparticles. J Mater Chem 18(23):2629-2635
76. Ma DL et al (2007) Superparamagnetic Fe(x)Oy@SiO2 core-shell nanostructures: controlled synthesis and magnetic characterization. J Phys Chem C 111(5):1999-2007
77. Fuertges F, Abuchowski A (1990) The clinical efficacy of poly(ethylene glycol)-modified proteins. J Controlled Release 11(1-3):139-148
78. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214-221
79. Lutz JF et al (2006) One-pot synthesis of PEGylated ultrasmall iron-oxide nanoparticles and their in vivo evaluation as magnetic resonance imaging contrast agents. Biomacromolecules 7(11):3132-3138
80. Kim SW et al (2005) Phosphine oxide polymer for water-soluble nanoparticles. J Am Chem Soc 127(13):4556-4557
81. Xu CJ et al (2004) Dopamine as a robust anchor to immobilize functional molecules on the iron oxide shell of magnetic nanoparticles. J Am Chem Soc 126(32):9938-9939
82. Amstad E et al (2009) Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. Nano Lett 9(12):4042-4048
83. Jaiswal MK et al (2014) Thermoresponsive magnetic hydrogels as theranostic nanoconstructs. ACS Appl Mater Interfaces 6(9):6237-6247
84. Molday RS, Mackenzie D (1982) Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods 52(3):353-367
85. Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452 (7187):580-589
86. Medarova Z et al (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13(3):372-377
87. Kumar M et al (2010) Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 70(19):7553-7561
88. DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643-8653
89. Kohler N et al (2006) Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2(6):785-792
90. Sun C et al (2008) In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4(3):372-379
91. Bautista MC et al (2005) Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. J Magn Magn Mater 293(1):20-27
92. Wunderbaldinger P, Josephson L, Weissleder R (2002) Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 9:S304-S306
93. Li W et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21(1):46-52
94. Lu Y et al (2002) Modifying the surface properties of superparamagnetic iron oxide nanoparticles through a sol-gel approach. Nano Lett 2(3):183-186
95. Pinho SLC et al (2010) Fine tuning of the relaxometry of gamma-Fe2O3@SiO2 nanoparticles by tweaking the silica coating thickness. ACS Nano 4(9):5339-5349
96. Liong M et al (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2(5):889-896
97. Aslam M, Li S, Dravid VP (2007) Controlled synthesis and stability of Co@SiO2 aqueous colloids. J Am Ceram Soc 90(3):950-956
98. Yoo JW, Chambers E, Mitragotri S (2010) Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des 16 (21):2298-2307
99. Chouly C et al (1996) Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 13(3):245-255
100. Gupta AK, Wells S (2004) Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobiosci 3 (1):66-73
101. Decuzzi P et al (2006) The effective dispersion of nanovectors within the tumor microvasculature. Ann Biomed Eng 34(4):633-641
102. Chertok B, David AE, Yang VC (2010) Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 31(24):6317-6324
103. Sun CR et al (2010) PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 4(4):2402-2410
104. Larsen EKU et al (2009) Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 3(7):1947-1951
105. Yallapu MM et al (2010) PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res 27(11):2283-2295
106. Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3(5):703-717
107. Gratton SEA et al (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105(33):11613-11618
108. Moghimi SM (1995) Exploiting bone-marrow microvascular structure for drug-delivery and future therapies. Adv Drug Deliv Rev 17(1):61-73
109. Moghimi SM (1995) Mechanisms of splenic clearance of blood-cells and particles-towards development of new splenotropic agents. Adv Drug Deliv Rev 17(1):103-115
110. Villanueva A et al (2009) The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 20(11):115103
111. Maeda H et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 65(1-2):271-284
112. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241-263
113. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136-151
114. Prabhakar U et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73 (8):2412-2417
115. Zhang Y, Kohler N, Zhang MQ (2002) Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23(7):1553-1561
116. Sinha R et al (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5(8):1909-1917
117. Kohler N et al (2005) Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21(19):8858-8864
118. Sun C, Sze R, Zhang MQ (2006) Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res Part A 78A(3):550-557
119. Montet X, Weissleder R, Josephson L (2006) Imaging pancreatic cancer with a peptidenanoparticle conjugate targeted to normal pancreas. Bioconjug Chem 17(4):905-911
120. Gunn J et al (2008) A multimodal targeting nanoparticle for selectively labeling T cells. Small 4(6):712-715
121. Hong S et al (2007) The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 14(1):107-115
122. Chertok B et al (2007) Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Controlled Release 122(3):315-323
123. Dobson J (2006) Magnetic nanoparticles for drug delivery. Drug Dev Res 67(1):55-60
124. Wilson MW et al (2004) Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology 230(1):287-293
125. Bulte JWM, Kraitchman DL (2004) Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 17(7):484-499
126. Artemov D et al (2003) MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49(3):403-408
127. Hu FQ et al (2006) Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer. Adv Mater 18(19):2553-2556
128. Xie J et al (2008) Ultrasmall c(RGDyK)-coated Fe(3)O(4) nanoparticles and their specific targeting to integrin alpha(v)beta(3)-rich tumor cells. J Am Chem Soc 130(24):7542
129. Bulte JWM et al (2001) Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 19(12):1141-1147
130. Frank JA et al (2003) Clinically applicable labeling of mammalian and stem cells by combining; superparamagnetic iron oxides and transfection agents. Radiology 228 (2):480-487
131. Bulte JWM (2009) In vivo MRI cell tracking: clinical studies. Am J Roentgenol 193 (2):314-325
132. Berman SMC, Walczak P, Bulte JWM (2011) Tracking stem cells using magnetic nanoparticles. Wiley Interdisc Rev Nanomed Nanobiotechnol 3(4):343-355
133. Ahrens ET, Bulte JWM (2013) Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol 13(10):755-763
134. Srivastava AK, Bulte JWM (2014) Seeing stem cells at work in vivo. Stem Cell Rev Rep 10 (1):127-144
135. Kircher MF et al (2003) In vivo high resolution three-dimensional imaging of antigenspecific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 63(20):6838-6846
136. Daldrup-Link HE et al (2005) In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 15(1):4-13
137. Anderson SA et al (2004) Magnetic resonance imaging of labeled T-Cells in a mouse model of multiple sclerosis. Ann Neurol 55(5):654-659
138. Berman SMC et al (2013) Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis. Magn Reson Med 69(1):255-262
139. de Vries IJM et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23(11):1407-1413
140. Verdijk P et al (2007) Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer 120(5):978-984
141. Verdijk P et al (2009) Limited amounts of dendritic cells migrate into the T-Cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15(7):2531-2540
142. Schuurhuis DH et al (2009) In situ expression of tumor antigens by messenger RNAelectroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 69 (7):2927-2934
143. Cruz LJ et al (2011) multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol Pharm 8(2):520-531
144. Janowski M et al (2014) Long-term MRI cell tracking after intraventricular delivery in a patient with global cerebral ischemia and prospects for magnetic navigation of stem cells within the CSF. PLoS ONE 9(6):e97631
145. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53(2):283-318
146. Huang J et al (2010) Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 4(12):7151-7160
147. Joshi HM et al (2009) Effects of shape and size of cobalt ferrite nanostructures on their MRI contrast and thermal activation. J Phys Chem C 113(41):17761-17767
148. Zhao ZH et al (2013) Octapod iron oxide nanoparticles as high-performance T-2 contrast agents for magnetic resonance imaging. Nat Commun 4:2266
149. Berret JF et al (2006) Controlled clustering of superparamagnetic nanoparticles using block copolymers: design of new contrast agents for magnetic resonance imaging. J Am Chem Soc 128(5):1755-1761
150. Lee JE et al (2010) Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 132(2):552-557
151. Barick KC et al (2009) Nanoscale assembly of amine-functionalized colloidal iron oxide. J Magn Magn Mater 321(10):1529-1532
152. LaConte LEW et al (2007) Coating thickness of magnetic iron oxide nanoparticles affects R-2 relaxivity. J Magn Reson Imaging 26(6):1634-1641
153. Gao JH et al (2008) Multifunctional yolk-shell nanoparticles: a potential MRI contrast and anticancer agent. J Am Chem Soc 130(35):11828-11833
154. Mahmoudi M et al (2011) Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 63(1-2):24-46
155. Pollert E et al (2009) Search of new core materials for magnetic fluid hyperthermia: preliminary chemical and physical issues. Prog Solid State Chem 37(1):1-14
156. Lacroix LM et al (2009) Magnetic hyperthermia in single-domain monodisperse FeCo nanoparticles: evidences for Stoner-Wohlfarth behavior and large losses. J Appl Phys 105 (2):023911
157. Mehdaoui B et al (2010) Large specific absorption rates in the magnetic hyperthermia properties of metallic iron nanocubes. J Magn Magn Mater 322(19):L49-L52
158. Franchini MC et al (2010) Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: a potential theranostic approach against cancer. Small 6 (3):366-370
159. Lee J-H et al (2011) Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nano 6(7):418-422
160. Yoo D et al (2012) Double-effector nanoparticles: a synergistic approach to apoptotic hyperthermia. Angew Chem Int Ed 51(50):12482-12485
161. Mykhaylyk O et al (2008) siRNA delivery by magnetofection. Curr Opin Mol Ther 10 (5):493-505
162. McBain SC et al (2008) Magnetic nanoparticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays. Nanotechnology 19(40):405102
163. Petri-Fink A et al (2008) Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies. Eur J Pharm Biopharm 68(1):129-137
164. Kievit FM et al (2009) PEI-PEG-Chitosan-copolymer-coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 19 (14):2244-2251
165. Kievit FM et al (2010) Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 4(8):4587-4594
166. Shin JM et al (2009) Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Ed 48(2):321-324
167. Cheng K et al (2009) Porous hollow Fe3O4 nanoparticles for targeted delivery and controlled release of cisplatin. J Am Chem Soc 131(30):10637-10644
168. Jain TK et al (2008) Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 29(29):4012-4021
169. Thomas CR et al (2010) Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc 132 (31):10623-10625
170. Purushotham S, Ramanujan RV (2010) Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapy. Acta Biomater 6(2):502-510